Advertisement
Screener

NovaBridge Biosciences (NBP) Form 6-K: Report of foreign private issuer, 2025

1.6 / 5 stars · 9/29 Roast Me

Add as a preferred source on Google

NovaBridge Biosciences Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2025-12-18: Form 6-K; Period of report 2025-09-30; Description 6-K; Document nbp-20250930.htm.
  • 2025-12-10: Form 6-K; Period of report 2025-12-10; Description 6-K; Document pr_-_esmo_io_poster_-_12.htm.
  • 2025-12-04: Form 6-K; Period of report 2025-12-03; Description 6-K; Document pr_-_esmo_io_abstract_-_.htm.
  • 2025-10-31: Form 6-K; Period of report 2025-10-31; Description FORM 6-K; Document d46723d6k.htm.
FiledFormPeriod of reportDescriptionDocument
2025-12-186-K2025-09-306-Knbp-20250930.htm
2025-12-106-K2025-12-106-Kpr_-_esmo_io_poster_-_12.htm
2025-12-046-K2025-12-036-Kpr_-_esmo_io_abstract_-_.htm
2025-10-316-K2025-10-31FORM 6-Kd46723d6k.htm
2025-10-306-K2025-10-296-Keverest_and_woo_pr_10-29.htm
2025-10-296-K2025-10-296-Kname_and_ticker_pr_10-29.htm
2025-10-286-K2025-10-286-Kbridge_health_close_-_10.htm
2025-10-246-K2025-10-246-Kegm_results_-_10-24-25.htm
2025-10-246-K2025-10-246-K3x_meeting_poster_-_24_o.htm
2025-10-246-K/A2025-10-246-K/Abusiness_update_-_10-21-.htm
2025-10-236-K2025-10-236-K3x_meeting_slides_-_23_o.htm
2025-10-226-K2025-10-226-Kpr_-_triple_meeting_-_10.htm
2025-10-166-K2025-10-166-Kbusiness_update_10-16-25.htm
2025-10-066-K2025-06-306-Kimab-20250630.htm
2025-09-246-K2025-09-246-Knotice_of_egm_9-24-25.htm
2025-09-086-K2025-09-036-Kgiva_and_exec_updates_-_.htm
2025-08-256-K2025-08-226-Kpr_-_new_bod_members_-_8.htm
2025-08-206-K2025-08-206-Ki-mab_6k_q2_2025.htm
2025-08-116-K2025-08-116-Kpr_-_12mg_cohort_lpi.htm
2025-08-046-K2025-08-046-Kd846500d6k.htm
2025-08-016-K2025-08-016-Kd24360d6k.htm
2025-07-176-K2025-07-176-Kpr_-_bridge_health_-_7-1.htm
2025-07-116-K2025-07-116-Kcayman_counsel_opinion.htm
2025-07-116-K/A2025-07-116-K/Aesmo_gi_-_7-11-25_amende.htm
2025-07-026-K2025-07-026-Kpr_-_esmo_gi_-_7-02-25.htm
2025-06-266-K2025-06-266-Kpr_-_esmo_abstract_pr_-_.htm
2025-06-126-K2025-06-126-Knasdaq_notice_-_6-12-25.htm
2025-06-026-K2025-06-026-Kimab_investor_present_06.htm
2025-05-306-K2025-05-306-Knew_director_-_sean_cao.htm
2025-05-156-K2025-05-146-Ki-mab_6k_q1_2025.htm
2025-04-306-K2025-04-306-Kpr_-_esmo_acceptance_-_4.htm
2025-04-046-K2025-04-046-Kimab_investor_present_04.htm
2025-04-036-K2025-04-036-Ki-mab_6k_q4_2024.htm
2025-03-216-K2025-03-216-Knasdaq_notice_-_3-21-25.htm
2025-03-076-K2025-03-076-Kpr_-_giva_update_-_3-6-2.htm
2025-02-276-K2025-02-276-Kimab_investor_present_2.htm
2025-01-296-K2025-01-296-Kworkforce_reduction_1.28.htm
2025-01-136-K2025-01-136-Kinvestor_presentation_1.htm
2025-01-086-K2025-01-086-Kwei_fu_share_purchase_1.htm
2025-01-066-K2025-01-066-Kgiva_1.6.2024_lead_progr.htm
Advertisement